OHSU

Stephen E.F. Spurgeon, M.D.

Head Shot of Stephen Spurgeon
Email: 
click here
Office: 
503 494-5058

Background

Dr. Spurgeon's research focuses on translating lab findings into new therapies in chronic lymphocytic leukemia and lymphoma, particularly mantle cell lymphoma.

Dr. Spurgeon has a special interest in: 1) unlocking the importance of cell signaling in lymphoid cancer pathogenesis, 2) identifying new therapeutic targets, 3) developing novel clinical trials, and 4) designing personalized treatment approaches.

CLL: Specifically, he is interested in the role of tyrosine kinases and B cell receptor (BCR) mediated signaling in leukemogenesis in chronic lymphocytic leukemia (CLL). He hopes to develop kinase directed treatment approaches for CLL. He also is interested in determining if in vitro kinase targeted drug screens can help predict in vivo response to anti-leukemic therapy. This includes collaborations with Dr. Marc Loriaux, Dr. Jeffrey Tyner and Dr. Brian Druker in the Center for Cell Signaling.

Lymphoma: In collaboration with Dr. Craig Okada at OHSU and Dr. Elliot Epner at Penn State, Dr. Spurgeon is exploring the role of epigenetic therapy in B cell malignancies especially in mantle cell lymphoma. Specifically, he is conducting an early phase clinical trial using cladribine, rituximab and vorniostat in relapsed B cell malignancies and newly diagnosed mantle cell lymphoma and CLL. This study evaluates DNA methylation patterns in patients on therapy and hopes to identify important target genes modified by this combination therapy.


Summary of Current Research

Knight Cancer Institute Clinical Research Review Committee (CRRC) Member Guest Lecturer Leukemia and Lymphoma Society

Research Interests:

Chronic lymphocytic leukemia, indolent lymphoma, intermediate and high-risk lymphoma, B-cell signaling, novel therapeutic targets, clinical trials


Selected Publications

"A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia," Blood (Vol: 123, Issue: 9, Page 1302-1308) - 2014

"A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)," Blood (Vol: 123, Issue: 22, Page 3398-3405) - 2014

"A potential therapeutic strategy for chronic lymphocytic leukemia by combining idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor," Oncotarget (Vol: 5, Issue: 4, Page 908-915) - 2014

"Aberrations of MYC are a common event in B-cell prolymphocytic leukemia," American Journal of Clinical Pathology (Vol: 142, Issue: 3, Page 347-354) - 2014

"Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma," Blood (Vol: 123, Issue: 22, Page 3406-3413) - 2014

 

OHSU Knight Cancer Institute

Visit Our Site

For Healthcare Professionals


Contact

  Email Stephen Spurgeon

503 494-5058

Memberships & Associations

American Society of Oncology American Society of Hematology Southwest Oncology Group Alpha Omega Alpha